Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
We broke ground on a second cGMP facility for our
#GeneTherapy treatments for skin conditions. The Astra facility is intended to support potential commercial production of B-VEC, formerly KB103, as well as ongoing R&D efforts. Full details here: http://bit.ly/2GuRPHQ pic.twitter.com/Xk6pVCTYZX
-
CEO Krish S. Krishnan will be presenting a corporate update at the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York on Tuesday December 3 at 9:10 a.m. ET. Webcast link for the presentation can be found here: http://bit.ly/34n1XfL
#GeneTherapy#Dermatologypic.twitter.com/clBSD005RV
-
In the final data update from the Phase 1/2 trial of KB103, now B-VEC, the topical
#GeneTherapy induced rapid and durable wound closure in patients with dystrophic#EpidermolysisBullosa and was safe and well-tolerated. Read the full release here: http://bit.ly/2JxeaX4 pic.twitter.com/18PTKSILJC
-
The EMA Committee for Orphan Medicinal Products issued a positive opinion on our orphan designation application for KB105, our second
#GeneTherapy treatment, for patients with transglutaminase-1 deficient autosomal recessive congenital ichthyosis: http://bit.ly/2Vw6Cs8@EMANewspic.twitter.com/E2UKyCFn8J
-
A new
#ClinicalTrial was just initiated and will study topical#GeneTherapy KB105 for treatment of#RareDisease transglutaminase-1 (TGM1) deficient autosomal recessive congenital#ichthyosis (ARCI). Read more about the trial here: http://bit.ly/2kr29Jy#dermatologypic.twitter.com/tKNm3DhWSX
-
CEO Krish Krishnan shares his advice with
@SBDealmakers on raising capital in#biotech and on how previous success in the industry paved the way for an initially self-funded company and a rapid IPO. Read the full story here: http://bit.ly/2Ur6jOV#DealmakersPittsburghpic.twitter.com/LgsQYMWB5b
-
KB103 study coordinator Dr. Peter Marinkovich was featured in
@TheDermEditor speaking about trial results, future plans and the hope this developmental#GeneTherapy could give to all those affected by dystrophic#EpidermolysisBullosa. Read it here: http://bit.ly/2TT5xKj pic.twitter.com/F5DFkHX5EF
-
Krystal reports second quarter 2019 financial results including recent milestones and program updates. Full release here: http://bit.ly/2T8Q0Wq
$KRYSpic.twitter.com/8DqfwE6i5n
-
Data from the Phase 2 GEM2 study show that KB103 was well-tolerated and induced rapid & durable wound closure in adult & pediatric patients with dystrophic
#EpidermolysisBullosa. Granted RMAT designation paves way for a planned pivotal Phase 3 before 2020. http://bit.ly/2XDb4ct pic.twitter.com/cggoryLLsd
-
We submitted an IND for a new
#GeneTherapy candidate, KB105, for patients with the#RareDisease TGM-1 deficient autosomal recessive congenital ichthyosis (“ARCI”). Read the full release here: http://bit.ly/2WKEPYS#Ichthyosis$KRYSpic.twitter.com/NuF3ImekRf
-
KB103, our clinical-stage first-in-class topical
#GeneTherapy for the treatment of dystrophic#EpidermolysisBullosa, was granted PRIME eligibility by@EMA_News, allowing for frequent and early interactions with the EMA to accelerate development: http://bit.ly/2I0hs5g pic.twitter.com/iAJg5ZU5ta
-
We celebrated the opening of Ancoris, our GMP facility for all production needs for KB103, our developmental
#GeneTherapy treatment for dystrophic#EpidermolysisBullosa. We were honored to be joined by@billpeduto@debraOfAmerica@SenToomey@SenBobCasey: http://bit.ly/2TzFBWm pic.twitter.com/55SCvUWY48
-
Join us in welcoming the newest member of our Board of Directors, Julian S Gangolli, whose vast experience with product launches will be invaluable as we progress our lead developmental product KB103 towards commercialization. For more details, see here: http://bit.ly/2VFK5bz pic.twitter.com/hvgp2Jo98Q
-
We've dosed the final 4 pediatric and adult
#EpidermolysisBullosa patients of 6 total in the GEM-Phase 2#ClinicalTrial with KB103, the first-ever topically-applied#GeneTherapy for this devastating#RareDisease. Top-line results in 1H2019. Read more here http://bit.ly/2LpM4wE pic.twitter.com/WSWSX7kF88
-
.@EBPartner is the largest non-profit organization dedicated to funding research for
#EpidermolysisBullosa. To date this organization has raised over $25 million to find the best treatment options for this disease. Learn more about them here: https://www.ebresearch.org/#EBWeekpic.twitter.com/BJrjooSvQi
-
We are proud to be partners with the
#EBMRF. This organization is unique because almost all of the donations they receive go to developing research programs in the hope of finding a cure for#EpidermolysisBullosa. Check them out here: https://ebmrf.org/#EverydayEB#EBweekpic.twitter.com/jGn6hNZiH8
-
Want to help raise awareness during
#EBweek? Join@CureEBorg in its#EBpop social media campaign by recording a video of yourself popping a water balloon to “help make the blisters stop”#EverydayEB https://bit.ly/2yqFRLu pic.twitter.com/fFVLwmHje0
-
We are honored to have received a Partners in Progress award from
@debraOfAmerica for our efforts to develop potentially life-changing new treatments for everyone affected by#EpidermolysisBullosa. We are stronger when we stand together with our allies to#FightEBpic.twitter.com/020FRXF6pC
-
Today is the first day of
#EBweek! Tonight we will be attending the 20th annual@debraOfAmerica Benefit which honors key people who have had a major impact in#EpidermolysisBullosa awareness. Team DEBRA does so much to help raise awareness for#EB: http://www.debra.org/ pic.twitter.com/2ku07kwUBZ
-
Today we announced positive interim data from our first-in-human study of KB103 in patients with
#EpidermolysisBullosa. The topically-applied#GeneTherapy hit primary and secondary endpoints with no safety concerns. Read here for more info: http://bit.ly/2PAUker#FightEBpic.twitter.com/Z7WmLkYW42
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.